Due to the advantages in efficacy and safety compared with traditional chemotherapy drugs,
targeted therapeutic drugs have become mainstream cancer treatments. Since the first …

Myeloproliferative neoplasm (MPN)-associated myelofibrosis (MF) is characterized by
cytopenias, marrow fibrosis, constitutional symptoms, extramedullary hematopoiesis …

Signal Transducer and Activator of Transcription (STAT) 3 and 5 are important effectors of
cellular transformation, and aberrant STAT3 and STAT5 signaling have been demonstrated …

FLT3 kinase is a potential drug target in acute myeloid leukemia (AML). Patients with FLT3
mutations typically have higher relapse rates and worse outcomes than patients without …

Abstract Over 30–35% of patients down with AML are caused by mutations of FLT3‐ITD and
FLT3‐TKD which keeps the protein activated while it activates other signaling proteins …

Therapeutic effects of FLT3 inhibitors have been reported in acute myeloid leukemia (AML)
with constitutively activating FLT3 mutations, including internal tandem duplication (ITD) and …

Background TAPUR is a pragmatic, phase II basket study evaluating the antitumor activity of
commercially available targeted agents in patients with advanced cancers harboring …

Opinion statement Acute myeloid leukemia (AML) disease prognosis is poor and there is a
high risk of chemo-resistant relapse for both young and old patients. Thus, there is a …

Acute myeloid leukemia (AML) is a highly aggressive illness distinguished by the
accumulation of abnormal hematopoietic precursors in both the bone marrow and peripheral …

FLT3 is considered a potential target of acute myeloid leukemia therapy. In this study, we
applied a computer-aided methodology unifying molecular docking and pharmacophore …